Details of the Drug

General Information of Drug (ID: DMKFQJP)

Drug Name
Triflupromazine
Synonyms
Adazine; Fluopromazine; Fluorofen; Neoprin; Nivoman; Psyquil; Siquil; Trifluopromazine; Triflupromazina; Triflupromazinum;Vesprin; Vetame; Fluopromazine monohydrochloride; Trifluopromazine hydrochloride; Triflupromazine [INN]; Triflupromazina [INN-Spanish]; Triflupromazinum [INN-Latin]; Vesprin (TN); Triflupromazine (USP/INN)
Indication
Disease Entry ICD 11 Status REF
Psychotic disorder 6A20-6A25 Approved [1], [2]
Therapeutic Class
Antipsychotic Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 1 Molecular Weight (mw) 352.4
Topological Polar Surface Area (xlogp) 5.2
Rotatable Bond Count (rotbonds) 4
Hydrogen Bond Donor Count (hbonddonor) 0
Hydrogen Bond Acceptor Count (hbondacc) 6
Chemical Identifiers
Formula
C18H19F3N2S
IUPAC Name
N,N-dimethyl-3-[2-(trifluoromethyl)phenothiazin-10-yl]propan-1-amine
Canonical SMILES
CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)C(F)(F)F
InChI
InChI=1S/C18H19F3N2S/c1-22(2)10-5-11-23-14-6-3-4-7-16(14)24-17-9-8-13(12-15(17)23)18(19,20)21/h3-4,6-9,12H,5,10-11H2,1-2H3
InChIKey
XSCGXQMFQXDFCW-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
5568
ChEBI ID
CHEBI:9711
CAS Number
146-54-3
DrugBank ID
DB00508
TTD ID
D05NOS
VARIDT ID
DR01359

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
5-HT 2B receptor (HTR2B) TT0K1SC 5HT2B_HUMAN Antagonist [3]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [4]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Psychotic disorder
ICD Disease Classification 6A20-6A25
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
5-HT 2B receptor (HTR2B) DTT HTR2B 2.08E-01 -0.05 -0.23
P-glycoprotein 1 (ABCB1) DTP P-GP 7.83E-01 4.69E-02 1.89E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Triflupromazine
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Fluphenazine DMIT8LX Moderate Additive anticholinergic effects by the combination of Triflupromazine and Fluphenazine. Psychotic disorder [6A20-6A25] [17]
Coadministration of a Drug Treating the Disease Different from Triflupromazine (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Ivosidenib DM8S6T7 Major Increased risk of prolong QT interval by the combination of Triflupromazine and Ivosidenib. Acute myeloid leukaemia [2A60] [18]
Midostaurin DMI6E0R Moderate Increased risk of prolong QT interval by the combination of Triflupromazine and Midostaurin. Acute myeloid leukaemia [2A60] [19]
Idarubicin DMM0XGL Moderate Increased risk of prolong QT interval by the combination of Triflupromazine and Idarubicin. Acute myeloid leukaemia [2A60] [19]
Daunorubicin DMQUSBT Moderate Increased risk of prolong QT interval by the combination of Triflupromazine and Daunorubicin. Acute myeloid leukaemia [2A60] [19]
Arn-509 DMT81LZ Moderate Increased risk of prolong QT interval by the combination of Triflupromazine and Arn-509. Acute myeloid leukaemia [2A60] [20]
Gilteritinib DMWQ4MZ Moderate Increased risk of prolong QT interval by the combination of Triflupromazine and Gilteritinib. Acute myeloid leukaemia [2A60] [21]
Oliceridine DM6MDCF Major Additive CNS depression effects by the combination of Triflupromazine and Oliceridine. Acute pain [MG31] [22]
Scopolamine DMOM8AL Moderate Additive anticholinergic effects by the combination of Triflupromazine and Scopolamine. Addictive disorder [6C50-6C5Z] [17]
Mepyramine DMB4SFH Moderate Additive anticholinergic effects by the combination of Triflupromazine and Mepyramine. Allergic/hypersensitivity disorder [4A80-4A8Z] [23]
Memantine DMD9WSC Moderate Additive anticholinergic effects by the combination of Triflupromazine and Memantine. Alzheimer disease [8A20] [17]
Galantamine DMEO794 Moderate Antagonize the effect of Triflupromazine when combined with Galantamine. Alzheimer disease [8A20] [24]
Rivastigmine DMG629M Moderate Antagonize the effect of Triflupromazine when combined with Rivastigmine. Alzheimer disease [8A20] [24]
Metronidazole DMTIVEN Minor Increased risk of prolong QT interval by the combination of Triflupromazine and Metronidazole. Amoebiasis [1A36] [25]
Isosorbide dinitrate DMBI4JG Moderate Additive hypotensive effects by the combination of Triflupromazine and Isosorbide dinitrate. Anal fissure/fistula [DB50] [26]
Ivabradine DM0L594 Major Increased risk of ventricular arrhythmias by the combination of Triflupromazine and Ivabradine. Angina pectoris [BA40] [20]
Dronedarone DMA8FS5 Major Increased risk of prolong QT interval by the combination of Triflupromazine and Dronedarone. Angina pectoris [BA40] [19]
Amyl nitrite DMJKO05 Moderate Additive hypotensive effects by the combination of Triflupromazine and Amyl nitrite. Angina pectoris [BA40] [26]
Nifedipine DMSVOZT Moderate Additive hypotensive effects by the combination of Triflupromazine and Nifedipine. Angina pectoris [BA40] [26]
Bedaquiline DM3906J Major Increased risk of prolong QT interval by the combination of Triflupromazine and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [27]
Hydroxyzine DMF8Y74 Moderate Additive anticholinergic effects by the combination of Triflupromazine and Hydroxyzine. Anxiety disorder [6B00-6B0Z] [17]
Cilostazol DMZMSCT Moderate Increased risk of prolong QT interval by the combination of Triflupromazine and Cilostazol. Arterial occlusive disease [BD40] [19]
Posaconazole DMUL5EW Moderate Increased risk of prolong QT interval by the combination of Triflupromazine and Posaconazole. Aspergillosis [1F20] [19]
Levalbuterol DM5YBO1 Moderate Increased risk of prolong QT interval by the combination of Triflupromazine and Levalbuterol. Asthma [CA23] [28]
Terbutaline DMD4381 Moderate Increased risk of ventricular arrhythmias by the combination of Triflupromazine and Terbutaline. Asthma [CA23] [29]
Pirbuterol DMI5678 Moderate Increased risk of ventricular arrhythmias by the combination of Triflupromazine and Pirbuterol. Asthma [CA23] [28]
Salbutamol DMN9CWF Moderate Increased risk of prolong QT interval by the combination of Triflupromazine and Salbutamol. Asthma [CA23] [28]
Formoterol DMSOURV Moderate Increased risk of ventricular arrhythmias by the combination of Triflupromazine and Formoterol. Asthma [CA23] [29]
Lisdexamfetamine DM6W8V5 Moderate Antagonize the effect of Triflupromazine when combined with Lisdexamfetamine. Attention deficit hyperactivity disorder [6A05] [30]
Desipramine DMT2FDC Moderate Increased plasma concentrations of Triflupromazine and Desipramine due to competitive inhibition of the same metabolic pathway. Attention deficit hyperactivity disorder [6A05] [31]
Ofloxacin DM0VQN3 Moderate Increased risk of prolong QT interval by the combination of Triflupromazine and Ofloxacin. Bacterial infection [1A00-1C4Z] [32]
Ciprofloxacin XR DM2NLS9 Moderate Increased risk of prolong QT interval by the combination of Triflupromazine and Ciprofloxacin XR. Bacterial infection [1A00-1C4Z] [19]
Clarithromycin DM4M1SG Moderate Increased risk of prolong QT interval by the combination of Triflupromazine and Clarithromycin. Bacterial infection [1A00-1C4Z] [19]
Sulfamethoxazole DMB08GE Minor Increased risk of prolong QT interval by the combination of Triflupromazine and Sulfamethoxazole. Bacterial infection [1A00-1C4Z] [19]
Linezolid DMGFPU2 Moderate Additive CNS depression effects by the combination of Triflupromazine and Linezolid. Bacterial infection [1A00-1C4Z] [33]
Gemifloxacin DMHT34O Moderate Increased risk of prolong QT interval by the combination of Triflupromazine and Gemifloxacin. Bacterial infection [1A00-1C4Z] [32]
Norfloxacin DMIZ6W2 Moderate Increased risk of prolong QT interval by the combination of Triflupromazine and Norfloxacin. Bacterial infection [1A00-1C4Z] [25]
Levofloxacin DMS60RB Moderate Increased risk of prolong QT interval by the combination of Triflupromazine and Levofloxacin. Bacterial infection [1A00-1C4Z] [32]
Telithromycin DMZ4P3A Moderate Increased risk of prolong QT interval by the combination of Triflupromazine and Telithromycin. Bacterial infection [1A00-1C4Z] [19]
Retigabine DMGNYIH Moderate Increased risk of prolong QT interval by the combination of Triflupromazine and Retigabine. Behcet disease [4A62] [34]
Cariprazine DMJYDVK Moderate Additive anticholinergic effects by the combination of Triflupromazine and Cariprazine. Bipolar disorder [6A60] [17]
Loperamide DMOJZQ9 Moderate Additive antimotility effects by the combination of Triflupromazine and Loperamide. Bowel habit change [ME05] [35]
Eribulin DM1DX4Q Moderate Increased risk of prolong QT interval by the combination of Triflupromazine and Eribulin. Breast cancer [2C60-2C6Y] [19]
Lapatinib DM3BH1Y Moderate Increased risk of prolong QT interval by the combination of Triflupromazine and Lapatinib. Breast cancer [2C60-2C6Y] [19]
Tamoxifen DMLB0EZ Moderate Increased risk of prolong QT interval by the combination of Triflupromazine and Tamoxifen. Breast cancer [2C60-2C6Y] [19]
Toremifene DMQYUWG Major Increased risk of prolong QT interval by the combination of Triflupromazine and Toremifene. Breast cancer [2C60-2C6Y] [19]
Bosutinib DMTI8YE Moderate Increased risk of prolong QT interval by the combination of Triflupromazine and Bosutinib. Breast cancer [2C60-2C6Y] [20]
Acetylcholine DMDF79Z Moderate Antagonize the effect of Triflupromazine when combined with Acetylcholine. Cataract [9B10] [36]
PF-04449913 DMSB068 Moderate Increased risk of prolong QT interval by the combination of Triflupromazine and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [37]
Umeclidinium DM4E8O9 Moderate Additive anticholinergic effects by the combination of Triflupromazine and Umeclidinium. Chronic obstructive pulmonary disease [CA22] [38]
Olodaterol DM62B78 Moderate Increased risk of ventricular arrhythmias by the combination of Triflupromazine and Olodaterol. Chronic obstructive pulmonary disease [CA22] [29]
Vilanterol DMF5EK1 Moderate Increased risk of ventricular arrhythmias by the combination of Triflupromazine and Vilanterol. Chronic obstructive pulmonary disease [CA22] [28]
Tiotropium DMFDC0Q Moderate Additive anticholinergic effects by the combination of Triflupromazine and Tiotropium. Chronic obstructive pulmonary disease [CA22] [38]
Salmeterol DMIEU69 Moderate Increased risk of ventricular arrhythmias by the combination of Triflupromazine and Salmeterol. Chronic obstructive pulmonary disease [CA22] [29]
Revefenacin DMMP5SI Moderate Additive anticholinergic effects by the combination of Triflupromazine and Revefenacin. Chronic obstructive pulmonary disease [CA22] [38]
Indacaterol DMQJHR7 Moderate Increased risk of prolong QT interval by the combination of Triflupromazine and Indacaterol. Chronic obstructive pulmonary disease [CA22] [29]
Arformoterol DMYM974 Moderate Increased risk of ventricular arrhythmias by the combination of Triflupromazine and Arformoterol. Chronic obstructive pulmonary disease [CA22] [29]
Dihydrocodeine DMB0FWL Major Additive CNS depression effects by the combination of Triflupromazine and Dihydrocodeine. Chronic pain [MG30] [22]
Oxaliplatin DMQNWRD Moderate Increased risk of prolong QT interval by the combination of Triflupromazine and Oxaliplatin. Colorectal cancer [2B91] [19]
Isoproterenol DMK7MEY Moderate Increased risk of prolong QT interval by the combination of Triflupromazine and Isoproterenol. Conduction disorder [BC63] [28]
Olopatadine DMKMWQG Moderate Additive CNS depression effects by the combination of Triflupromazine and Olopatadine. Conjunctiva disorder [9A60] [39]
Halothane DM80OZ5 Moderate Increased risk of prolong QT interval by the combination of Triflupromazine and Halothane. Corneal disease [9A76-9A78] [19]
Propofol DMB4OLE Moderate Increased risk of prolong QT interval by the combination of Triflupromazine and Propofol. Corneal disease [9A76-9A78] [40]
Sevoflurane DMC9O43 Moderate Increased risk of prolong QT interval by the combination of Triflupromazine and Sevoflurane. Corneal disease [9A76-9A78] [19]
Remifentanil DMZTXCH Major Additive CNS depression effects by the combination of Triflupromazine and Remifentanil. Corneal disease [9A76-9A78] [41]
Clofazimine DMEBOFW Moderate Increased risk of prolong QT interval by the combination of Triflupromazine and Clofazimine. Crohn disease [DD70] [42]
Pasireotide DMHM7JS Major Increased risk of prolong QT interval by the combination of Triflupromazine and Pasireotide. Cushing syndrome [5A70] [19]
Sertraline DM0FB1J Moderate Increased risk of prolong QT interval by the combination of Triflupromazine and Sertraline. Depression [6A70-6A7Z] [19]
Trimipramine DM1SC8M Moderate Increased plasma concentrations of Triflupromazine and Trimipramine due to competitive inhibition of the same metabolic pathway. Depression [6A70-6A7Z] [31]
Nortriptyline DM4KDYJ Moderate Increased plasma concentrations of Triflupromazine and Nortriptyline due to competitive inhibition of the same metabolic pathway. Depression [6A70-6A7Z] [31]
Paroxetine DM5PVQE Moderate Decreased metabolism of Triflupromazine caused by Paroxetine mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [43]
Selegiline DM6034S Moderate Additive hypotensive effects by the combination of Triflupromazine and Selegiline. Depression [6A70-6A7Z] [33]
Isocarboxazid DMAF1NB Moderate Additive CNS depression effects by the combination of Triflupromazine and Isocarboxazid. Depression [6A70-6A7Z] [33]
Escitalopram DMFK9HG Major Increased risk of prolong QT interval by the combination of Triflupromazine and Escitalopram. Depression [6A70-6A7Z] [19]
Tranylcypromine DMGB5RE Moderate Additive hypotensive effects by the combination of Triflupromazine and Tranylcypromine. Depression [6A70-6A7Z] [44]
OPC-34712 DMHG57U Moderate Additive anticholinergic effects by the combination of Triflupromazine and OPC-34712. Depression [6A70-6A7Z] [17]
Phenelzine DMHIDUE Moderate Additive hypotensive effects by the combination of Triflupromazine and Phenelzine. Depression [6A70-6A7Z] [33]
Clomipramine DMINRKW Moderate Increased plasma concentrations of Triflupromazine and Clomipramine due to competitive inhibition of the same metabolic pathway. Depression [6A70-6A7Z] [31]
Amoxapine DMKITQE Moderate Increased plasma concentrations of Triflupromazine and Amoxapine due to competitive inhibition of the same metabolic pathway. Depression [6A70-6A7Z] [31]
Doxepin DMPI98T Moderate Increased plasma concentrations of Triflupromazine and Doxepin due to competitive inhibition of the same metabolic pathway. Depression [6A70-6A7Z] [45]
Maprotiline DMPWB7T Moderate Additive anticholinergic effects by the combination of Triflupromazine and Maprotiline. Depression [6A70-6A7Z] [17]
Esketamine DMVU687 Moderate Additive CNS depression effects by the combination of Triflupromazine and Esketamine. Depression [6A70-6A7Z] [25]
Nitroglycerin DMQ2491 Moderate Additive hypotensive effects by the combination of Triflupromazine and Nitroglycerin. Diabetic foot ulcer [BD54] [26]
Mepenzolate DM8YU2F Moderate Additive anticholinergic effects by the combination of Triflupromazine and Mepenzolate. Digestive system disease [DE2Z] [23]
Oxybutynine DMJPBAX Moderate Additive anticholinergic effects by the combination of Triflupromazine and Oxybutynine. Discovery agent [N.A.] [17]
Tetrabenazine DMYWQ0O Major Additive antidopaminergic effects by the combination of Triflupromazine and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [46]
Meclizine DMS7T13 Moderate Additive anticholinergic effects by the combination of Triflupromazine and Meclizine. Dizziness and giddiness [MB48] [17]
Deutetrabenazine DMUPFLI Major Additive antidopaminergic effects by the combination of Triflupromazine and Deutetrabenazine. Dystonic disorder [8A02] [47]
Ingrezza DMVPLNC Moderate Increased risk of prolong QT interval by the combination of Triflupromazine and Ingrezza. Dystonic disorder [8A02] [48]
Zonisamide DM0DTF7 Major Increased risk of hyperpyrexia by the combination of Triflupromazine and Zonisamide. Epilepsy/seizure [8A61-8A6Z] [49]
Diphenhydramine DMKQTBA Moderate Antagonize the effect of Triflupromazine when combined with Diphenhydramine. Episodic vestibular syndrome [AB31] [50]
Guanabenz DM5QWEL Moderate Additive hypotensive effects by the combination of Triflupromazine and Guanabenz. Essential hypertension [BA00] [51]
Phenoxybenzamine DM8KSQH Moderate Additive hypotensive effects by the combination of Triflupromazine and Phenoxybenzamine. Essential hypertension [BA00] [26]
Nicardipine DMCDYW7 Moderate Additive hypotensive effects by the combination of Triflupromazine and Nicardipine. Essential hypertension [BA00] [26]
Nadolol DMW6GVL Moderate Additive hypotensive effects by the combination of Triflupromazine and Nadolol. Essential hypertension [BA00] [26]
Solifenacin DMG592Q Moderate Increased risk of prolong QT interval by the combination of Triflupromazine and Solifenacin. Functional bladder disorder [GC50] [19]
Tolterodine DMSHPW8 Moderate Additive anticholinergic effects by the combination of Triflupromazine and Tolterodine. Functional bladder disorder [GC50] [17]
Pentamidine DMHZJCG Moderate Increased risk of prolong QT interval by the combination of Triflupromazine and Pentamidine. Fungal infection [1F29-1F2F] [19]
Terbinafine DMI6HUW Moderate Decreased metabolism of Triflupromazine caused by Terbinafine mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [52]
Phentolamine DMXYJOB Moderate Additive hypotensive effects by the combination of Triflupromazine and Phentolamine. Gangrene [MC85] [26]
Propantheline DM2EN6G Moderate Additive anticholinergic effects by the combination of Triflupromazine and Propantheline. Gastric ulcer [DA60] [17]
Sunitinib DMCBJSR Moderate Increased risk of prolong QT interval by the combination of Triflupromazine and Sunitinib. Gastrointestinal stromal tumour [2B5B] [19]
Pilocarpine DMV9ADG Moderate Antagonize the effect of Triflupromazine when combined with Pilocarpine. Glaucoma [9C61] [36]
Eplerenone DMF0NQR Moderate Additive hypotensive effects by the combination of Triflupromazine and Eplerenone. Heart failure [BD10-BD1Z] [26]
Carvedilol DMHTEAO Moderate Additive hypotensive effects by the combination of Triflupromazine and Carvedilol. Heart failure [BD10-BD1Z] [26]
Chlorothiazide DMLHESP Moderate Increased risk of ventricular arrhythmias by the combination of Triflupromazine and Chlorothiazide. Heart failure [BD10-BD1Z] [25]
Furosemide DMMQ8ZG Moderate Increased risk of ventricular arrhythmias by the combination of Triflupromazine and Furosemide. Heart failure [BD10-BD1Z] [25]
Amiloride DMRTSGP Moderate Additive hypotensive effects by the combination of Triflupromazine and Amiloride. Heart failure [BD10-BD1Z] [26]
Bumetanide DMRV7H0 Moderate Increased risk of ventricular arrhythmias by the combination of Triflupromazine and Bumetanide. Heart failure [BD10-BD1Z] [25]
Hydroflumethiazide DMVPUQI Moderate Increased risk of ventricular arrhythmias by the combination of Triflupromazine and Hydroflumethiazide. Heart failure [BD10-BD1Z] [25]
Procarbazine DMIK367 Moderate Additive hypotensive effects by the combination of Triflupromazine and Procarbazine. Hodgkin lymphoma [2B30] [33]
Fostemsavir DM50ILT Moderate Increased risk of prolong QT interval by the combination of Triflupromazine and Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [53]
Efavirenz DMC0GSJ Major Increased risk of prolong QT interval by the combination of Triflupromazine and Efavirenz. Human immunodeficiency virus disease [1C60-1C62] [54]
Saquinavir DMG814N Major Increased risk of prolong QT interval by the combination of Triflupromazine and Saquinavir. Human immunodeficiency virus disease [1C60-1C62] [55]
Rilpivirine DMJ0QOW Moderate Increased risk of prolong QT interval by the combination of Triflupromazine and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [19]
Isosorbide mononitrate DMYLMU0 Moderate Additive hypotensive effects by the combination of Triflupromazine and Isosorbide mononitrate. Hydrocephalus [8D64] [26]
Eprosartan DM07K2I Moderate Additive hypotensive effects by the combination of Triflupromazine and Eprosartan. Hypertension [BA00-BA04] [26]
Acebutolol DM0TI4U Moderate Additive hypotensive effects by the combination of Triflupromazine and Acebutolol. Hypertension [BA00-BA04] [26]
Moexipril DM26E4B Moderate Additive hypotensive effects by the combination of Triflupromazine and Moexipril. Hypertension [BA00-BA04] [26]
Bisoprolol DM3UZ95 Moderate Additive hypotensive effects by the combination of Triflupromazine and Bisoprolol. Hypertension [BA00-BA04] [26]
Captopril DM458UM Moderate Additive hypotensive effects by the combination of Triflupromazine and Captopril. Hypertension [BA00-BA04] [26]
Trandolapril DM4L6EU Moderate Additive hypotensive effects by the combination of Triflupromazine and Trandolapril. Hypertension [BA00-BA04] [26]
Methyldopa DM5I621 Moderate Additive hypotensive effects by the combination of Triflupromazine and Methyldopa. Hypertension [BA00-BA04] [26]
Clonidine DM6RZ9Q Moderate Additive hypotensive effects by the combination of Triflupromazine and Clonidine. Hypertension [BA00-BA04] [26]
Losartan DM72JXH Moderate Additive hypotensive effects by the combination of Triflupromazine and Losartan. Hypertension [BA00-BA04] [26]
Nebivolol DM7F1PA Moderate Additive hypotensive effects by the combination of Triflupromazine and Nebivolol. Hypertension [BA00-BA04] [26]
Levamlodipine DM92S6N Moderate Additive hypotensive effects by the combination of Triflupromazine and Levamlodipine. Hypertension [BA00-BA04] [26]
Doxazosin DM9PLRH Moderate Additive hypotensive effects by the combination of Triflupromazine and Doxazosin. Hypertension [BA00-BA04] [26]
Verapamil DMA7PEW Moderate Additive hypotensive effects by the combination of Triflupromazine and Verapamil. Hypertension [BA00-BA04] [26]
TAK-491 DMCF6SX Moderate Additive hypotensive effects by the combination of Triflupromazine and TAK-491. Hypertension [BA00-BA04] [26]
Pindolol DMD2NV7 Moderate Additive hypotensive effects by the combination of Triflupromazine and Pindolol. Hypertension [BA00-BA04] [26]
Fenoldopam DMFAOKP Moderate Additive hypotensive effects by the combination of Triflupromazine and Fenoldopam. Hypertension [BA00-BA04] [26]
Indapamide DMGN1PW Moderate Increased risk of ventricular arrhythmias by the combination of Triflupromazine and Indapamide. Hypertension [BA00-BA04] [25]
Benazepril DMH1M9B Moderate Additive hypotensive effects by the combination of Triflupromazine and Benazepril. Hypertension [BA00-BA04] [26]
Labetalol DMK8U72 Moderate Additive hypotensive effects by the combination of Triflupromazine and Labetalol. Hypertension [BA00-BA04] [26]
Diazoxide DML1538 Moderate Additive hypotensive effects by the combination of Triflupromazine and Diazoxide. Hypertension [BA00-BA04] [26]
Perindopril DMOPZDT Moderate Additive hypotensive effects by the combination of Triflupromazine and Perindopril. Hypertension [BA00-BA04] [26]
Felodipine DMOSW35 Moderate Additive hypotensive effects by the combination of Triflupromazine and Felodipine. Hypertension [BA00-BA04] [26]
Quinapril DMR8H31 Moderate Additive hypotensive effects by the combination of Triflupromazine and Quinapril. Hypertension [BA00-BA04] [26]
Telmisartan DMS3GX2 Moderate Additive hypotensive effects by the combination of Triflupromazine and Telmisartan. Hypertension [BA00-BA04] [26]
Irbesartan DMTP1DC Moderate Additive hypotensive effects by the combination of Triflupromazine and Irbesartan. Hypertension [BA00-BA04] [26]
Hydralazine DMU8JGH Moderate Additive hypotensive effects by the combination of Triflupromazine and Hydralazine. Hypertension [BA00-BA04] [26]
Lisinopril DMUOK4C Moderate Additive hypotensive effects by the combination of Triflupromazine and Lisinopril. Hypertension [BA00-BA04] [26]
Hydrochlorothiazide DMUSZHD Moderate Increased risk of ventricular arrhythmias by the combination of Triflupromazine and Hydrochlorothiazide. Hypertension [BA00-BA04] [25]
Clevidipine butyrate DMW4M97 Moderate Additive hypotensive effects by the combination of Triflupromazine and Clevidipine butyrate. Hypertension [BA00-BA04] [26]
Amantadine DMS3YE9 Moderate Additive anticholinergic effects by the combination of Triflupromazine and Amantadine. Influenza [1E30-1E32] [56]
ITI-007 DMUQ1DO Moderate Additive anticholinergic effects by the combination of Triflupromazine and ITI-007. Insomnia [7A00-7A0Z] [17]
Polyethylene glycol DM4I1JP Moderate Increased risk of ventricular arrhythmias by the combination of Triflupromazine and Polyethylene glycol. Irritable bowel syndrome [DD91] [19]
Clidinium DMUMQZ0 Moderate Additive anticholinergic effects by the combination of Triflupromazine and Clidinium. Irritable bowel syndrome [DD91] [17]
Dicyclomine DMZSDGX Moderate Additive anticholinergic effects by the combination of Triflupromazine and Dicyclomine. Irritable bowel syndrome [DD91] [17]
Physostigmine DM2N0TO Moderate Antagonize the effect of Triflupromazine when combined with Physostigmine. Lips/oral mucosa miscellaneous disorder [DA02] [24]
Crizotinib DM4F29C Major Increased risk of prolong QT interval by the combination of Triflupromazine and Crizotinib. Lung cancer [2C25] [57]
Porfimer Sodium DM7ZWNY Moderate Increased risk of photosensitivity reactions by the combination of Triflupromazine and Porfimer Sodium. Lung cancer [2C25] [58]
Ceritinib DMB920Z Major Increased risk of prolong QT interval by the combination of Triflupromazine and Ceritinib. Lung cancer [2C25] [19]
Osimertinib DMRJLAT Major Increased risk of prolong QT interval by the combination of Triflupromazine and Osimertinib. Lung cancer [2C25] [59]
Selpercatinib DMZR15V Major Increased risk of prolong QT interval by the combination of Triflupromazine and Selpercatinib. Lung cancer [2C25] [60]
Chloroquine DMSI5CB Major Increased risk of prolong QT interval by the combination of Triflupromazine and Chloroquine. Malaria [1F40-1F45] [61]
Hydroxychloroquine DMSIVND Major Increased risk of prolong QT interval by the combination of Triflupromazine and Hydroxychloroquine. Malaria [1F40-1F45] [61]
Primaquine DMWQ16I Moderate Increased risk of prolong QT interval by the combination of Triflupromazine and Primaquine. Malaria [1F40-1F45] [19]
Inotuzumab ozogamicin DMAC130 Moderate Increased risk of prolong QT interval by the combination of Triflupromazine and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [20]
Arsenic trioxide DM61TA4 Major Increased risk of ventricular arrhythmias by the combination of Triflupromazine and Arsenic trioxide. Mature B-cell lymphoma [2A85] [62]
Vemurafenib DM62UG5 Major Increased risk of prolong QT interval by the combination of Triflupromazine and Vemurafenib. Melanoma [2C30] [19]
LGX818 DMNQXV8 Moderate Increased risk of prolong QT interval by the combination of Triflupromazine and LGX818. Melanoma [2C30] [63]
Allopregnanolone DMNLHAC Moderate Additive CNS depression effects by the combination of Triflupromazine and Allopregnanolone. Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z] [64]
Propranolol DM79NTF Moderate Additive hypotensive effects by the combination of Triflupromazine and Propranolol. Migraine [8A80] [26]
Lasmiditan DMXLVDT Moderate Additive CNS depression effects by the combination of Triflupromazine and Lasmiditan. Migraine [8A80] [65]
Flibanserin DM70DTN Moderate Additive CNS depression effects by the combination of Triflupromazine and Flibanserin. Mood disorder [6A60-6E23] [66]
Panobinostat DM58WKG Major Increased risk of prolong QT interval by the combination of Triflupromazine and Panobinostat. Multiple myeloma [2A83] [67]
Thalidomide DM70BU5 Moderate Additive CNS depression effects by the combination of Triflupromazine and Thalidomide. Multiple myeloma [2A83] [20]
Siponimod DM2R86O Major Increased risk of ventricular arrhythmias by the combination of Triflupromazine and Siponimod. Multiple sclerosis [8A40] [25]
Fingolimod DM5JVAN Major Increased risk of ventricular arrhythmias by the combination of Triflupromazine and Fingolimod. Multiple sclerosis [8A40] [19]
Ozanimod DMT6AM2 Major Increased risk of ventricular arrhythmias by the combination of Triflupromazine and Ozanimod. Multiple sclerosis [8A40] [68]
Methoxsalen DME8FZ9 Moderate Increased risk of photosensitivity reactions by the combination of Triflupromazine and Methoxsalen. Mycosis fungoides [2B01] [25]
Romidepsin DMT5GNL Moderate Increased risk of prolong QT interval by the combination of Triflupromazine and Romidepsin. Mycosis fungoides [2B01] [34]
Nilotinib DM7HXWT Major Increased risk of prolong QT interval by the combination of Triflupromazine and Nilotinib. Myeloproliferative neoplasm [2A20] [19]
Dasatinib DMJV2EK Moderate Increased risk of prolong QT interval by the combination of Triflupromazine and Dasatinib. Myeloproliferative neoplasm [2A20] [69]
Dextroamphetamine DMMIHVP Moderate Antagonize the effect of Triflupromazine when combined with Dextroamphetamine. Narcolepsy [7A20] [30]
Dimenhydrinate DM264B3 Moderate Additive anticholinergic effects by the combination of Triflupromazine and Dimenhydrinate. Nausea/vomiting [MD90] [17]
Promethazine DM6I5GR Moderate Additive anticholinergic effects by the combination of Triflupromazine and Promethazine. Nausea/vomiting [MD90] [17]
Metoclopramide DMFA5MY Major Additive antidopaminergic effects by the combination of Triflupromazine and Metoclopramide. Nausea/vomiting [MD90] [70]
Dolasetron DMMG26Z Major Increased risk of prolong QT interval by the combination of Triflupromazine and Dolasetron. Nausea/vomiting [MD90] [19]
Ondansetron DMOTQ1I Moderate Increased risk of prolong QT interval by the combination of Triflupromazine and Ondansetron. Nausea/vomiting [MD90] [19]
Entrectinib DMMPTLH Moderate Increased risk of prolong QT interval by the combination of Triflupromazine and Entrectinib. Non-small cell lung cancer [2C25] [20]
Phendimetrazine DM6TS1N Moderate Antagonize the effect of Triflupromazine when combined with Phendimetrazine. Obesity [5B80-5B81] [30]
Amfepramone DM9YSNQ Moderate Antagonize the effect of Triflupromazine when combined with Amfepramone. Obesity [5B80-5B81] [30]
Lorcaserin DMG6OYJ Moderate Increased risk of hyperprolactinemic effects by the combination of Triflupromazine and Lorcaserin. Obesity [5B80-5B81] [71]
Benzphetamine DMIJATC Moderate Antagonize the effect of Triflupromazine when combined with Benzphetamine. Obesity [5B80-5B81] [30]
Metolazone DMB39LO Moderate Increased risk of ventricular arrhythmias by the combination of Triflupromazine and Metolazone. Oedema [MG29] [25]
Polythiazide DMCH80F Moderate Increased risk of ventricular arrhythmias by the combination of Triflupromazine and Polythiazide. Oedema [MG29] [25]
Apraclonidine DMO4PVE Moderate Additive CNS depression effects by the combination of Triflupromazine and Apraclonidine. Optic nerve disorder [9C40] [72]
Rucaparib DM9PVX8 Moderate Increased risk of prolong QT interval by the combination of Triflupromazine and Rucaparib. Ovarian cancer [2C73] [19]
Pentazocine DM1XBHS Major Additive CNS depression effects by the combination of Triflupromazine and Pentazocine. Pain [MG30-MG3Z] [41]
Dextropropoxyphene DM23HCX Major Additive CNS depression effects by the combination of Triflupromazine and Dextropropoxyphene. Pain [MG30-MG3Z] [73]
Butorphanol DM5KYPJ Major Additive CNS depression effects by the combination of Triflupromazine and Butorphanol. Pain [MG30-MG3Z] [41]
Oxymorphone DM65AGJ Major Additive CNS depression effects by the combination of Triflupromazine and Oxymorphone. Pain [MG30-MG3Z] [41]
Levorphanol DMGS80V Major Additive CNS depression effects by the combination of Triflupromazine and Levorphanol. Pain [MG30-MG3Z] [41]
Flavoxate DMKV4NL Moderate Additive anticholinergic effects by the combination of Triflupromazine and Flavoxate. Pain [MG30-MG3Z] [17]
Nalbuphine DMOSQGU Major Additive CNS depression effects by the combination of Triflupromazine and Nalbuphine. Pain [MG30-MG3Z] [41]
Methamphetamine DMPM4SK Moderate Antagonize the effect of Triflupromazine when combined with Methamphetamine. Pain [MG30-MG3Z] [74]
Hydrocodone DMQ2JO5 Major Additive CNS depression effects by the combination of Triflupromazine and Hydrocodone. Pain [MG30-MG3Z] [41]
Triclabendazole DMPWGBR Moderate Increased risk of prolong QT interval by the combination of Triflupromazine and Triclabendazole. Parasitic worm infestation [1F90] [34]
Safinamide DM0YWJC Moderate Additive CNS depression effects by the combination of Triflupromazine and Safinamide. Parkinsonism [8A00] [33]
Pergolide DM14MAE Moderate Antagonize the effect of Triflupromazine when combined with Pergolide. Parkinsonism [8A00] [75]
Opicapone DM1BKA6 Moderate Antagonize the effect of Triflupromazine when combined with Opicapone. Parkinsonism [8A00] [76]
Rasagiline DM3WKQ4 Moderate Additive hypotensive effects by the combination of Triflupromazine and Rasagiline. Parkinsonism [8A00] [33]
Biperiden DME78OA Moderate Antagonize the effect of Triflupromazine when combined with Biperiden. Parkinsonism [8A00] [77]
Levodopa DMN3E57 Moderate Antagonize the effect of Triflupromazine when combined with Levodopa. Parkinsonism [8A00] [75]
Pimavanserin DMR7IVC Moderate Increased risk of prolong QT interval by the combination of Triflupromazine and Pimavanserin. Parkinsonism [8A00] [78]
Orphenadrine DMW542E Moderate Additive anticholinergic effects by the combination of Triflupromazine and Orphenadrine. Parkinsonism [8A00] [17]
Methylscopolamine DM5VWOB Moderate Additive anticholinergic effects by the combination of Triflupromazine and Methylscopolamine. Peptic ulcer [DA61] [17]
Famotidine DMRL3AB Moderate Increased risk of prolong QT interval by the combination of Triflupromazine and Famotidine. Peptic ulcer [DA61] [25]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Triflupromazine and Macimorelin. Pituitary gland disorder [5A60-5A61] [79]
Lefamulin DME6G97 Major Increased risk of prolong QT interval by the combination of Triflupromazine and Lefamulin. Pneumonia [CA40] [18]
Degarelix DM3O8QY Moderate Increased risk of prolong QT interval by the combination of Triflupromazine and Degarelix. Prostate cancer [2C82] [20]
ABIRATERONE DM8V75C Moderate Decreased metabolism of Triflupromazine caused by ABIRATERONE mediated inhibition of CYP450 enzyme. Prostate cancer [2C82] [80]
Nilutamide DMFN07X Moderate Increased risk of prolong QT interval by the combination of Triflupromazine and Nilutamide. Prostate cancer [2C82] [20]
Enzalutamide DMGL19D Moderate Increased risk of prolong QT interval by the combination of Triflupromazine and Enzalutamide. Prostate cancer [2C82] [20]
Bicalutamide DMZMSPF Moderate Increased risk of prolong QT interval by the combination of Triflupromazine and Bicalutamide. Prostate cancer [2C82] [20]
Terazosin DM3JCVS Moderate Additive hypotensive effects by the combination of Triflupromazine and Terazosin. Prostate hyperplasia [GA90] [26]
Tamsulosin DM5QF9V Moderate Additive hypotensive effects by the combination of Triflupromazine and Tamsulosin. Prostate hyperplasia [GA90] [26]
Silodosin DMJSBT6 Moderate Additive hypotensive effects by the combination of Triflupromazine and Silodosin. Prostate hyperplasia [GA90] [26]
Gatifloxacin DMSL679 Major Increased risk of prolong QT interval by the combination of Triflupromazine and Gatifloxacin. Respiratory infection [CA07-CA4Z] [81]
Neupro DMHEAB1 Moderate Antagonize the effect of Triflupromazine when combined with Neupro. Restless legs syndrome [7A80] [75]
Quetiapine DM1N62C Moderate Increased risk of prolong QT interval by the combination of Triflupromazine and Quetiapine. Schizophrenia [6A20] [19]
Mesoridazine DM2ZGAN Major Increased risk of prolong QT interval by the combination of Triflupromazine and Mesoridazine. Schizophrenia [6A20] [25]
Thioridazine DM35M8J Major Increased risk of prolong QT interval by the combination of Triflupromazine and Thioridazine. Schizophrenia [6A20] [82]
Aripiprazole DM3NUMH Moderate Additive anticholinergic effects by the combination of Triflupromazine and Aripiprazole. Schizophrenia [6A20] [17]
Iloperidone DM6AUFY Major Increased risk of prolong QT interval by the combination of Triflupromazine and Iloperidone. Schizophrenia [6A20] [19]
Paliperidone DM7NPJS Moderate Increased risk of prolong QT interval by the combination of Triflupromazine and Paliperidone. Schizophrenia [6A20] [19]
Perphenazine DMA4MRX Moderate Additive anticholinergic effects by the combination of Triflupromazine and Perphenazine. Schizophrenia [6A20] [17]
Molindone DMAH70G Moderate Additive anticholinergic effects by the combination of Triflupromazine and Molindone. Schizophrenia [6A20] [17]
Thiothixene DMDINC4 Moderate Additive anticholinergic effects by the combination of Triflupromazine and Thiothixene. Schizophrenia [6A20] [17]
Risperidone DMN6DXL Moderate Additive anticholinergic effects by the combination of Triflupromazine and Risperidone. Schizophrenia [6A20] [17]
Amisulpride DMSJVAM Major Increased risk of prolong QT interval by the combination of Triflupromazine and Amisulpride. Schizophrenia [6A20] [83]
Asenapine DMSQZE2 Moderate Increased risk of prolong QT interval by the combination of Triflupromazine and Asenapine. Schizophrenia [6A20] [19]
Pimozide DMW83TP Major Increased risk of prolong QT interval by the combination of Triflupromazine and Pimozide. Schizophrenia [6A20] [20]
Fentanyl DM8WAHT Major Additive CNS depression effects by the combination of Triflupromazine and Fentanyl. Sensation disturbance [MB40] [41]
Sufentanil DMU7YEL Major Additive CNS depression effects by the combination of Triflupromazine and Sufentanil. Sensation disturbance [MB40] [41]
Vardenafil DMTBGW8 Moderate Increased risk of prolong QT interval by the combination of Triflupromazine and Vardenafil. Sexual dysfunction [HA00-HA01] [19]
LEE011 DMMX75K Major Increased risk of prolong QT interval by the combination of Triflupromazine and LEE011. Solid tumour/cancer [2A00-2F9Z] [19]
Vandetanib DMRICNP Major Increased risk of prolong QT interval by the combination of Triflupromazine and Vandetanib. Solid tumour/cancer [2A00-2F9Z] [19]
Triptorelin DMTK4LS Moderate Increased risk of prolong QT interval by the combination of Triflupromazine and Triptorelin. Solid tumour/cancer [2A00-2F9Z] [20]
Doxorubicin DMVP5YE Moderate Increased risk of prolong QT interval by the combination of Triflupromazine and Doxorubicin. Solid tumour/cancer [2A00-2F9Z] [19]
Pitolisant DM8RFNJ Moderate Increased risk of prolong QT interval by the combination of Triflupromazine and Pitolisant. Somnolence [MG42] [19]
Telavancin DM58VQX Moderate Increased risk of prolong QT interval by the combination of Triflupromazine and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [19]
Adenosine DMM2NSK Moderate Increased risk of ventricular arrhythmias by the combination of Triflupromazine and Adenosine. Supraventricular tachyarrhythmia [BC81] [19]
Cabozantinib DMIYDT4 Major Increased risk of prolong QT interval by the combination of Triflupromazine and Cabozantinib. Thyroid cancer [2D10] [20]
Papaverine DMCA9QP Moderate Additive hypotensive effects by the combination of Triflupromazine and Papaverine. Tonus and reflex abnormality [MB47] [26]
Tizanidine DMR2IQ4 Moderate Additive CNS depression effects by the combination of Triflupromazine and Tizanidine. Tonus and reflex abnormality [MB47] [84]
Tacrolimus DMZ7XNQ Moderate Increased risk of prolong QT interval by the combination of Triflupromazine and Tacrolimus. Transplant rejection [NE84] [19]
Atropine DMEN6X7 Moderate Additive anticholinergic effects by the combination of Triflupromazine and Atropine. Unspecific substance harmful effect [NE6Z] [17]
Chlorpheniramine DM5URA2 Moderate Additive anticholinergic effects by the combination of Triflupromazine and Chlorpheniramine. Vasomotor/allergic rhinitis [CA08] [17]
Carbinoxamine DMCT31R Moderate Additive anticholinergic effects by the combination of Triflupromazine and Carbinoxamine. Vasomotor/allergic rhinitis [CA08] [17]
Acrivastine DMTIGA0 Moderate Additive anticholinergic effects by the combination of Triflupromazine and Acrivastine. Vasomotor/allergic rhinitis [CA08] [23]
Procainamide DMNMXR8 Major Increased risk of prolong QT interval by the combination of Triflupromazine and Procainamide. Ventricular tachyarrhythmia [BC71] [19]
Propafenone DMPIBJK Moderate Increased risk of prolong QT interval by the combination of Triflupromazine and Propafenone. Ventricular tachyarrhythmia [BC71] [19]
Flecainide DMSQDLE Moderate Increased risk of prolong QT interval by the combination of Triflupromazine and Flecainide. Ventricular tachyarrhythmia [BC71] [19]
Amiodarone DMUTEX3 Major Increased risk of prolong QT interval by the combination of Triflupromazine and Amiodarone. Ventricular tachyarrhythmia [BC71] [19]
⏷ Show the Full List of 257 DDI Information of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4330).
2 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 011123.
3 Some properties of 5-hydroxytryptamine receptors in the hindquarters of the rat. Br J Pharmacol. 1979 Sep;67(1):79-85.
4 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
5 MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
6 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
7 Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
8 Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
9 Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
10 Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
11 Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedebergs Arch Pharmacol. 2004 Aug;370(2):114-23.
12 Privileged structures: a useful concept for the rational design of new lead drug candidates. Mini Rev Med Chem. 2007 Nov;7(11):1108-19.
13 New Insights into the Mechanism of Action of Viloxazine: Serotonin and Norepinephrine Modulating Properties. J Exp Pharmacol. 2020 Aug 25;12:285-300.
14 Prediction of Efficacy of Vabicaserin, a 5-HT2C Agonist, for the Treatment of Schizophrenia Using a Quantitative Systems Pharmacology Model.CPT Pharmacometrics Syst Pharmacol.2014 Apr 23;3:e111.
15 Emerging treatments for pulmonary arterial hypertension. Expert Opin Emerg Drugs. 2006 Nov;11(4):609-19.
16 Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106.
17 Cohen MA, Alfonso CA, Mosquera M. Development of urinary retention during treatment with clozapine and meclizine [published correction appears in Am J Psychiatry 1994 Jun;151(6):952]. Am J Psychiatry. 1994;151(4):619-620. [PMID: 8147469]
18 Product Information. Fycompa (perampanel). Eisai Inc, Teaneck, NJ.
19 Canadian Pharmacists Association.
20 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
21 Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
22 US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
23 Kulik AV, Wilbur R "Delirium and stereotypy from anticholinergic antiparkinson drugs." Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82. [PMID: 7202232]
24 Beers MH, Ouslander JG, Rollingher I, Reuben DB, Brooks J, Beck JC "Explicit criteria for determining inappropriate medication use in nursing home residents." Arch Intern Med 151 (1991): 1825-32. [PMID: 1888249]
25 Cerner Multum, Inc. "Australian Product Information.".
26 Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30. [PMID: 7884028]
27 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
28 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
29 Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
30 Achor MB, Extein I "Diet aids, mania, and affective illness" Am J Psychiatry 138 (1981): 392. [PMID: 7468847]
31 Bock JL, Nelson JC, Gray S, Jatlow PI "Desipramine hydroxylation: variability and effect of antipsychotic drugs." Clin Pharmacol Ther 33 (1983): 322-8. [PMID: 6130865]
32 Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
33 Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6. [PMID: 1116424]
34 Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8. [PMID: 12904146]
35 Eronen M, Putkonen H, Hallikainen T, Vartiainen H "Lethal gastroenteritis associated with clozapine and loperamide." Am J Psychiatry 160 (2003): 2242-2243. [PMID: 14638602]
36 Multum Information Services, Inc. Expert Review Panel.
37 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
38 Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21. [PMID: 23170031]
39 Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
40 Hanci V, Aydin M, Yurtlu BS, et.al "Anesthesia induction with sevoflurane and propofol: evaluation of P-wave dispersion, QT and corrected QT intervals." Kaohsiung J Med Sci 26 (2010): 470-7. [PMID: 20837343]
41 US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
42 Product Information. Lamprene (clofazimine). Novartis Pharmaceuticals, East Hanover, NJ.
43 Nicholson SD "Extra pyramidal side effects associated with paroxetine." West Engl Med J 107 (1992): 90-1. [PMID: 1308691]
44 Goldberg LI "Monoamine oxidase inhibitors: adverse reactions and possible mechanisms." JAMA 190 (1964): 456-62. [PMID: 14197995]
45 Lee BS "Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs." J Clin Psychiatry 47 (1986): 571. [PMID: 3771507]
46 Burke RE, Fahn S, Mayeux R, Weinberg H, Louis K, Willner JH "Neuroleptic malignant syndrome caused by dopamine-depleting drugs in a patient with Huntington disease." Neurology 31 (1981): 1022-5. [PMID: 6115336]
47 Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
48 Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
49 Product Information. Zonegran (zonisamide) Elan Pharmaceuticals, S. San Francisco, CA.
50 Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA "Anticholinergic psychosis in a patient receiving usual doses of haloperidol." Clin Pharm 2 (1983): 174-8. [PMID: 6883947]
51 Product Information. Clozaril (clozapine). Novartis Pharmaceuticals, East Hanover, NJ.
52 AbdelRahman SM, Gotschall RR, Kauffman RE, Leeder JS, Kearns GL "Investigation of terbinafine as a CYP2D6 inhibitor in vivo." Clin Pharmacol Ther 65 (1999): 465-72. [PMID: 10340911]
53 Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
54 Product Information. Sustiva (efavirenz). DuPont Pharmaceuticals, Wilmington, DE.
55 Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
56 Postma JU, van Tilburg W "Visual hallucinations and delirium during treatment with amantadine (Symmetrel)." J Am Geriatr Soc 23 (1975): 212-5. [PMID: 123540]
57 Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
58 Blakely KM, Drucker AM, Rosen CF "Drug-induced photosensitivity-an update: Culprit drugs, prevention and management." Drug Saf 42 (2019): 827-47. [PMID: 30888626]
59 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
60 Product Information. Retevmo (selpercatinib). Lilly, Eli and Company, Indianapolis, IN.
61 Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
62 Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
63 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
64 Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
65 Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
66 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
67 Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
68 Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
69 Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
70 Bateman DN, Rawlins MD, Simpson JM "Extrapyramidal reactions with metoclopramide." Br Med J (Clin Res Ed) 291 (1985): 930-2. [PMID: 3929968]
71 Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):.
72 Product Information. Alphagan (brimonidine ophthalmic). Allergan Inc, Irvine, CA.
73 Abernethy DR, Greenblatt DJ, Steel K, Shader RI "Impairment of hepatic drug oxidation by propoxyphene." Ann Intern Med 97 (1982): 223-4. [PMID: 7103282]
74 Lake CR "Manic psychosis after coffee and phenylpropanolamine." Biol Psychiatry 30 (1991): 401-4. [PMID: 1912131]
75 Mims RB, Scott CL, Modebe O, Bethune JE "Inhibition of L-dopa-induced growth hormone stimulation by pyridoxine and chlorpromazine." J Clin Endocrinol Metab 40 (1975): 256-9. [PMID: 1117978]
76 Product Information. Norprolac (quinagolide). Ferring Inc, North York, IA.
77 Warnes H, Lehmann HE, Ban TA "Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases." Can Med Assoc J 96 (1967): 1112-3. [PMID: 6021058]
78 Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
79 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
80 Product Information. Zytiga (abiraterone). Centocor Inc, Malvern, PA.
81 Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004): 55-6. [PMID: 14722399]
82 El-Yousef MK, Manier DH "Tricyclic antidepressants and phenothiazines." JAMA 229 (1974): 1419. [PMID: 4152942]
83 Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.
84 Product Information. Zanaflex (tizanidine). Acorda Therapeutics, Hawthorne, NY.